Galera Therapeutics, Inc.
Galera Therapeutics, Inc. (GRTX): 4 pipeline candidates · ~19 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.4 months
D/E 1.57 · 31% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Galera Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$17.3M
Cash
$5.5M
Quarterly Burn
$875K
Runway
19.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| avasopasem | Phase 1 |
| avasopasem manganese | Phase 3 |
| l-nmma | Phase 1/Phase 2 |
| rucosopasem manganese | Phase 2 |
Frequently asked questions
How many drug candidates are in Galera Therapeutics, Inc.'s pipeline?
Galera Therapeutics, Inc. (GRTX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Galera Therapeutics, Inc.'s lead drug candidate?
Galera Therapeutics, Inc.'s most advanced tracked candidate is avasopasem (Phase 1) for Hormone receptor positive (HR+) breast cancer.
What is Galera Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Galera Therapeutics, Inc. has approximately 19.4 months of cash runway.
What is Galera Therapeutics, Inc.'s market capitalization?
Galera Therapeutics, Inc.'s market capitalization is approximately $17.3M.
Who is the CEO of Galera Therapeutics, Inc.?
Dr. J. Mel Sorensen M.D. is the chief executive officer of Galera Therapeutics, Inc. (GRTX).
Get the full picture on Galera Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.